Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.

ABSTRACT:

Background

Even though virtually all patients with Ewing sarcoma achieve a radiographic complete response, up to 30% of patients who present with localized disease and up to 90% of those who present with metastases experience a metastatic disease recurrence, highlighting the inability to identify patients with residual disease at the end of therapy. Up to 95% of Ewing sarcomas carry a driving EWS-ETS translocation that has an intronic breakpoint that is specific to each tumor, and the authors developed a system to quantitatively detect the specific breakpoint DNA fragment in patient plasma.

Methods

The authors used a long-range multiplex polymerase chain reaction (PCR) technique to identify tumor-specific EWS-ETS breakpoints in Ewing sarcoma cell lines, patient-derived xenog

SUBMITTER: Hayashi M 

PROVIDER: S-EPMC5102400 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature